SCHEMBL10061648

SCHEMBL10061648

CC(=O)OCCCCC(O)CO

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
USP2 O75604 3/20 0.41
CYP3A4 P08684 2/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
HPGD P15428 1/20 0.41
TP53 P04637 1/20 0.41
MAPK1 P28482 1/20 0.41
PLA2G2C Q5R387 1/20 0.41
CHRM5 P08912 2/20 0.38
CHRM1 P11229 2/20 0.38
CHRM3 P20309 2/20 0.38
LMNA P02545 2/20 0.38
PGR P06401 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
HTR1A P08908 1/20 0.38
CHRNB2 P17787 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28170344 0.86 ALDH1A1 (0.47) ALDH1A1USP2CYP3A4MAPTSMN1; SMN2
SCHEMBL7700789 0.85 ALOX15 (0.44) ALDH1A1USP2CYP3A4MAPTSMN1; SMN2
SCHEMBL5988620 0.85 ALOX15 (0.44) ALDH1A1USP2CYP3A4MAPTSMN1; SMN2
SCHEMBL18968288 0.82 ALDH1A1 (0.52) ALDH1A1USP2CYP3A4MAPTSMN1; SMN2
SCHEMBL18968287 0.82 ALDH1A1 (0.52) ALDH1A1USP2CYP3A4MAPTSMN1; SMN2
Acetic Acid Pentyl Ester SCHEMBL27372452 0.82 ALDH1A1 (0.63) ALDH1A1USP2MEN1KMT2APLA2G2C
SCHEMBL1556186 0.82 ALDH1A1 (0.57) ALDH1A1USP2CYP3A4MAPTSMN1; SMN2
SCHEMBL18968313 0.82 ALDH1A1 (0.52) ALDH1A1USP2CYP3A4MAPTSMN1; SMN2
SCHEMBL891129 0.82 TSHR (0.56) ALDH1A1USP2CYP3A4MAPTSMN1; SMN2
SCHEMBL4544191 0.82 ALDH1A1 (0.50) ALDH1A1USP2CYP3A4MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407547-B2 Methods of producing compounds from 5-(halomethyl)furfural MICROMIDAS, INC. (US) 2019-09-10 US disclosed
WO-2015175528-A1 METHODS OF PRODUCING COMPOUNDS FROM 5-(HALOMETHYL)FURFURAL MICROMIDAS, INC. (US) 2015-11-19 WO disclosed
US-8268959-B2 Suitable for binding high explosives, and may also be used as explosives in their own right; materials possess high energy density and are highly amenable to chemical modification thereby allowing for modification to the physical properties of the material; tacky and rubbery nature THE SECRETARY OF STATE FOR DEFENSE (GB) 2012-09-18 US disclosed
EP-2460842-A2 Novel energetic polyphosphazenes The Secretary of State For Defence (GB) 2012-06-06 EP disclosed
US-20120053356-A1 NOVEL ENERGETIC POLYPHOSPHAZENES THE SECRETARY OF STATE FOR DEFENSE (GB) 2012-03-01 US disclosed
US-20080108784-A1 Suitable for binding high explosives, and may also be used as explosives in their own right; materials possess high energy density and are highly amenable to chemical modification thereby allowing for modification to the physical properties of the material; tacky and rubbery nature DEFENSE, THE SECRETARY OF THE STATE FOR (GB) 2008-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10407547-B2 Methods of producing compounds from 5-(halomethyl)furfural HDHD5, HPD, DCXR ALDH1A1 1961/4885USP2 1413/4885CYP3A4 555/4885
US-20120053356-A1 NOVEL ENERGETIC POLYPHOSPHAZENES ACLY, PEBP1, DDX42 ALDH1A1 4205/4885USP2 3431/4885CYP3A4 4192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.